Terms ending in 2027
Every in-force patent on Hoffmann-La Roche Inc.'s record whose computed term ends in 2027, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 7,425,551 | Malonamide Derivatives In force · High confidence | Hoffmann-La Roche Inc. | In force | High confidence | |
| US 7,514,426 | Substituted Imidazol[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine Derivatives In force · Medium confidence | Hoffmann-La Roche Inc. | In force | Medium confidence | |
| US 11,673,958 | Glycosylated Antibodies In force · Low confidence | Hoffmann-La Roche Inc. | In force | Low confidence | |
| US 7,504,544 | Asymmetric Hydrogenation of 1,1,1- Trifluoroacetone In force · High confidence | Hoffmann-La Roche Inc. | In force | High confidence | |
| US 7,642,264 | Phenyl-Substituted Pyrimidine Derivatives as MG1UR Antagonists In force · High confidence | Hoffmann-La Roche Inc. | In force | High confidence | |
| US 7,955,806 | Detection of a Therapeutic Antibody in an Experimental Animal In force · High confidence | Hoffmann-La Roche, Inc. | In force | High confidence | |
| US 12,559,561 | Glycosylated Antibodies In force · Medium confidence | Hoffmann-La Roche Inc. | In force | Medium confidence | |
| US 8,889,109 | Novel Pharmaceutical Dosage Forms Comprising Valganciclovir Hydrochloride In force · Medium confidence | Cheplapharm Arzneimittel GmbH | In force | Medium confidence | |
| US 9,642,911 | Novel Pharmaceutical Dosage Forms Comprising Valganciclovir Hydrochloride In force · Medium confidence | Cheplapharm Arzneimittel GmbH | In force | Medium confidence | |
| US 11,185,588 | Novel Pharmaceutical Dosage Forms Comprising Valganciclovir Hydrochloride In force · Medium confidence | Cheplapharm Arzneimittel GmbH | In force | Medium confidence |
10 of 10 patents shown. Soonest term end first, then patent number.
7 of these are in force and held by Hoffmann-La Roche Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.